Welcome to our dedicated page for Pliant Therapeutics SEC filings (Ticker: PLRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biopharmaceutical company focused on integrin-based therapeutics. These regulatory documents offer detailed information on the company’s financial condition, clinical development activities, risk factors and corporate governance.
Through periodic reports such as Forms 10-Q and 10-K, Pliant describes research and development spending, progress in programs like bexotegrast (PLN-74809) for idiopathic pulmonary fibrosis, PLN-101095 for solid tumors and PLN-101325 for muscular dystrophies, as well as broader platform efforts in integrin-based drug discovery. Current reports on Form 8-K, including those referenced in the provided data, disclose specific material events such as financial results for a quarter, voluntary prepayment and termination of a loan agreement, changes in executive leadership roles and other significant corporate actions.
Investors can also review filings that discuss strategic realignments of workforce and operations, cash runway considerations and references to risk factors and management’s discussion and analysis sections, which Pliant points to in its press releases. For those tracking equity and governance details, the company’s registration of common stock and related rights on The Nasdaq Stock Market LLC is reflected in its SEC submissions.
On Stock Titan, these filings are available alongside AI-powered summaries that highlight key points, helping readers interpret lengthy documents such as annual and quarterly reports or event-driven 8-Ks. Real-time updates from the SEC’s EDGAR system, combined with structured access to filings related to financial results, material agreements and leadership changes, allow users to follow how Pliant’s disclosures develop over time.
Pliant Therapeutics President and CEO Bernard Coulie reported a sale of 89,375 shares of common stock on January 20, 2026 at a weighted average price of
After this transaction, Coulie directly beneficially owns 505,601 shares of common stock, which include 1,959 shares acquired through an employee stock purchase program. He is also reported as indirectly owning 409,317 shares held by The Coulie/Leyman Family Trust, where he and his spouse serve as trustees; he disclaims beneficial ownership of those shares beyond his pecuniary interest.
Pliant Therapeutics, Inc. Chief Operating Officer Minnie Kuo had 6,917 shares of common stock sold on January 20, 2026 at a price of $1.28 per share. This was a nondiscretionary sale by a plan under Rule 10b5-1, carried out by a broker as part of transactions at prices ranging from $1.245 to $1.33 between January 20 and January 22, 2026. The sales were made on behalf of a group of employees, including Kuo, to cover withholding taxes related to the vesting of previously granted restricted stock units. After this transaction, Kuo beneficially owned 37,806 shares of Pliant Therapeutics common stock directly.
Pliant Therapeutics, Inc. disclosed that investment entities affiliated with Citadel and Kenneth Griffin have reported a significant shareholding in its common stock. Mr. Griffin may be deemed to beneficially own 2,991,915 Shares of Pliant, representing 4.9% of the Shares outstanding, based on 61,449,385 Shares outstanding as of November 1, 2025 from the company’s Form 10-Q. Various Citadel entities report smaller positions, with Citadel Advisors-related entities at 3.4%, Citadel Securities LLC at 1.4%, and other Citadel Securities affiliates at 1.5%.
The filing states that all reported Shares, which may include instruments convertible into Shares, are held as of the market open on January 22, 2026. The reporting group certifies that the securities were not acquired and are not held for the purpose of changing or influencing control of Pliant, indicating a passive investment posture under the relevant ownership rules.
Morgan Stanley filed an amended Schedule 13G/A reporting its beneficial ownership in Pliant Therapeutics, Inc. common stock. The firm reports beneficial ownership of 545,228 shares, with shared voting power over 544,224 shares and shared dispositive power over 545,228 shares. This position represents 0.9% of Pliant’s common stock as of the event date of 12/31/2025.
Morgan Stanley notes that, as of this date, it has ceased to be the beneficial owner of more than five percent of this class of securities. The filing also states that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of Pliant Therapeutics.
Pliant Therapeutics, Inc. reported an executive leadership change, appointing Minnie Kuo as Chief Operating Officer effective December 10, 2025. She previously served as the company’s Chief Development Officer after joining in September 2023.
Kuo is described as an experienced biotechnology and pharmaceutical executive with more than 20 years of multinational clinical development experience across respiratory, oncology, neurodegenerative, inflammatory, and infectious diseases. Her prior roles included senior positions at Vir Biotechnology, Nektar Therapeutics, Gilead Sciences, Roche/Genentech, and several clinical research organizations.
The company states that Ms. Kuo received no additional compensation at the time of her appointment as Chief Operating Officer and that there are no disclosable family relationships or related-party transactions associated with her appointment.
Pliant Therapeutics (PLRX) filed its Q3 2025 10-Q, reporting a net loss of $26.3 million for the quarter and $125.8 million year‑to‑date. Operating expenses fell sharply as the company wound down its discontinued IPF program.
Research and development expense decreased to $17.9 million (from $47.8 million a year ago), and general and administrative fell to $10.3 million (from $14.3 million). Cash, cash equivalents and short‑term investments were $243.3 million as of September 30, 2025. Net cash used in operating activities was $110.5 million for the nine months ended September 30, 2025.
The company discontinued bexotegrast in IPF after safety‑related findings and completed a restructuring that reduced its workforce by approximately 45%. In oncology, the Phase 1 trial of PLN‑101095 completed enrollment; data, including higher dose cohorts, are expected by the end of 2025. After quarter‑end, Pliant voluntarily prepaid its Oxford loan for $32.4 million, terminating the facility. Shares outstanding were 61,449,385 as of November 1, 2025.
Pliant Therapeutics filed an 8‑K announcing it furnished a press release with financial results for the third quarter ended September 30, 2025. The press release is attached as Exhibit 99.1. The company states the information in this report, including the exhibit, is furnished under Item 2.02 and is not deemed “filed” under Section 18 of the Exchange Act. The report was signed by Keith Cummings, M.D., MBA, Chief Financial Officer.
Pliant Therapeutics reported an executive change: Chief Business Officer Hans Hull resigned effective October 20, 2025. The company stated the resignation was not due to any disagreement related to operations, policies, or practices. The report was signed by Keith Cummings, M.D., MBA, in his capacity as Chief Financial Officer.
Pliant Therapeutics, Inc. (PLRX) fully repaid its debt facility, making a voluntary payoff of $32.4 million on October 14, 2025 to settle all outstanding principal, accrued interest, fees and expenses under its Amended and Restated Loan and Security Agreement with Oxford Finance. With receipt of the payoff, all obligations were discharged and the loan documents were terminated.
The agreement allowed up to $150 million in term loans; the company had borrowed $30 million. The loans bore a floating rate tied to 1‑month SOFR with a 3.5% add‑on plus 5.25%, subject to a floor of 8.75%. Scheduled amortization would have begun on July 1, 2028, but the company chose early repayment, eliminating future interest and covenant requirements tied to this facility.
Point72 Asset Management and affiliates report beneficial ownership of 4,085,017 shares of Pliant Therapeutics, Inc. (PLRX), representing 6.7% of the outstanding common stock as of the close of business on September 3, 2025. The filing is a Schedule 13G showing that Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen share voting and dispositive power over these shares and that the shares are held by an investment fund managed by Point72 Asset Management (Point72 Associates).
The statement clarifies that none of the reporting persons own shares directly and that Point72 Associates has the right to receive dividends or sale proceeds for more than 5% of the class. A Joint Filing Agreement (Exhibit 99.1) is referenced.